Jinna Li

Jinna Li

Auto-generated profile, based on publicly available information

Jinna Li

Department of Radiation Oncology, Peking University 3rd Hospital, Huan-yuan North Road 49th, Beijing 100083, P. R. China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2013 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HWHao Wang
Hao Wang
JWJunjie Wang
Junjie Wang
YJYuliang Jiang
Yuliang Jiang
JLJinna Li
Jinna Li
STSuqing Tian
Suqing Tian
YGYang Gao
Yang Gao
To assess the efficacy of intraoperative ultrasound-guided implantation of 125I seeds for the treatment of unresectable pancreatic carcinoma, and analyze the associated prognostic factors.

23 June 2009 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JWJunjie Wang
Junjie Wang
YJYuliang Jiang
Yuliang Jiang
JLJinna Li
Jinna Li
STSuqing Tian
Suqing Tian
WRWeiqiang Ran
Weiqiang Ran
DXDianrong Xiu
Dianrong Xiu
To assess the feasibility and efficacy of using 125I seed implantation under intraoperative ultrasound guidance for unresectable pancreatic carcinoma. Fourteen patients with pancreatic carcinoma that underwent laparotomy and considered unresectable were included in this study. Nine patients were pathologically diagnosed with Stage II disease, five patients with Stage III disease. Fourteen patients were treated with 125I seed implantation guided by intraoperative ultrasound and received D90 of 125I seeds ranging from 60 to 140 Gy with a median of 120 Gy. Five patients received an additional 35-50 Gy from external beam radiotherapy after seed implantation and six patients received 2-6 cycles of chemotherapy. 87.5% (7/8) of patients received partial to complete pain relief. The response rate of tumor was 78.6%, One-, two-and three-year survival rates were 33.9% and 16.9%, 7.8%, with local control of disease achieved in 78.6% (11/14), and the median survival was 10 months (95% CI: 7.7-12.3). There were no deaths related to 125I seed implant. In this preliminary investigation, 125I seed implant provided excellent palliation of pain relief, local control and prolong the survival of patients with stage II and III disease to some extent.